NCT02269189View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

November 30, 2002

Conditions
Cystic Fibrosis
Interventions
DRUG

BIIL 284 BS, high dose

DRUG

BIIL 284 BS, low dose

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY